Wall Street Zen downgrades Edwards Lifesciences stock to Hold
Published on 10/01/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Wall Street Zen downgraded Edwards Lifesciences stock from Buy to Hold on September 26, 2026, according to MarketBeat. The move contrasts with a broader analyst consensus that still carries a Moderate Buy label and an average target of USD 100.27.
Analyst split meets solid growth
Edwards Lifesciences reported USD 1.74 billion in revenue for the second quarter of 2026, compared with USD 1.53 billion in the same quarter of 2025. MarketBeat reported that quarterly earnings per share reached USD 0.78, above the USD 0.74 consensus estimate, while revenue exceeded the USD 1.70 billion forecast.
Net profit for the second quarter was USD 241.9 million, compared with USD 329.8 million a year earlier, making the revenue expansion more important for the earnings narrative. Edwards also set third-quarter 2026 earnings-per-share guidance at USD 0.71 to USD 0.77 and full-year 2026 guidance at USD 2.95 to USD 3.05, according to MarketBeat.
Targets point above the quote
Leerink Partners reiterated its Buy rating and set a USD 101.00 price target on September 29, 2026, as reported by Markets Insider. The same report put the analyst consensus target at USD 103.40, while the June 30 quarterly figures showed the tension between higher revenue and lower net profit.
Edwards Lifesciences develops structural heart devices, including transcatheter valve systems and surgical heart products. Its business profile gives the analyst debate a specific operating anchor: revenue growth is being weighed against quarterly profitability and the company's guidance range.
Stock stays inside its yearly range
Edwards Lifesciences was trading at EUR 75.99 at Lang & Schwarz on October 1, 2026 at 4:43 p.m. CEST, minus 0.34 percent versus the prior close of EUR 76.25 on September 30, 2026. The primary listing is on the NYSE in USD, with a 52-week range of USD 72.30 to USD 96.29 and market capitalization of USD 49.3 billion as of October 1, 2026. Gekko lists October 29, 2026 as the next earnings date.
The further course of trading is shown by the continuously updated real-time quote of Edwards Lifesciences stock.
Edwards Lifesciences market data
- Company: Edwards Lifesciences Corporation
- ISIN: US28176E1082
- Ticker: EW
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 1, 2026, 4:43 p.m. CEST: EUR 75.99
- Change versus prior close: minus 0.34 percent
- Prior close Lang & Schwarz September 30, 2026: EUR 76.25
- Market capitalization: USD 49.3 billion as of October 1, 2026
- 52-week range: USD 72.30-USD 96.29 as of September 26, 2026
- Sector / Industry: Healthcare / Medical devices
- Index membership: S&P 500
- Next earnings date: October 29, 2026
